← All Sponsors

SPONSOR

Valent Technologies, LLC

Total Trials

1

Recruiting

1

Phases

Phase 1

Conditions studied: Solid Tumors Neuroblastoma Rhabdomyosarcoma Ewing Sarcoma Hepatoblastoma Medulloblastoma

NCT04337177 Phase 1

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors